Abstract: Real-world users of an event simulation system can playback a digital representation of an event that is mapped onto a virtual model of a real-world venue to simulate the event being presented at a real-world venue. As the real-world users are viewing this virtual event, these users can virtually interact with the virtual event, for example, move around the virtual event to view the virtual event at various locations and/or modify parameters, characteristics, and/or attributes of the virtual event. Thereafter, the event simulation system can propagate these modifications across multiple real-world users of the event simulation system to allow these real-world users to collaboratively interact with the virtual event.

Abstract: A vapor compression system includes an indoor heat exchanger, an outdoor heat exchanger, a compressor, a first valve, and a second valve. The compressor has an inlet connected to a suction flow and an exit connected to a discharge flow. The first valve is movable to connect the discharge flow to one of the indoor and outdoor heat exchangers. The second valve is movable to connect the suction flow to one of the indoor and outdoor heat exchangers.

Abstract: This document relates to a process for deploying devices and automatically provisioning the devices to connect to a managed network upon powering on with minimal user involvement. Upon deployment of the device to an end point, a record can be established in a management server regarding the device, which can associate device specifications with a deployment profile to be used in provisioning the device. Upon powering on of the device at the end point, the device can automatically perform attestation with the management server, which can then provision the device according to the deployment profile without additional user intervention.

Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

Abstract: A system may include a first compressor, a second compressor, a first heat exchanger and a second heat exchanger. The first compressor has a first inlet and a first outlet. The second compressor is a sumpless compressor and has a second inlet and a second outlet. The second compressor provides working fluid discharged from the second outlet to the first compressor. The first heat exchanger is disposed upstream of the second compressor and provides working fluid to the second compressor. The second heat exchanger is disposed upstream of the first compressor and provides working fluid to the first compressor.

Abstract: A DC disconnector comprising a static electrical contact, at least one moveable electrical contact comprising a plurality of conductor blades, and a shaft, coupled to the movable electrical contact. The shaft is configured to actuate the moveable electrical contact between a first configuration and a second configuration, wherein at least a portion of each conductor blade abuts the static electrical contact in the first configuration, and wherein the plurality of conductor blades are displaced from the static electrical contact in the second configuration.

Abstract: The present disclosure is directed to edible organogel compositions that comprise an organogelator and a flavor component, and processes for preparing the organogel compositions. The organogel compositions may be included as the flavor component in confectionery products, such as chewing gums.

Abstract: A refrigerant control system includes: a charge module configured to determine an amount of refrigerant that is present within a first portion of a refrigeration system within a building; and an isolation module configured to selectively open and close an isolation valve of the refrigeration system and to, via the isolation valve, maintain the amount of refrigerant within the first portion within the building below a predetermined amount of the refrigerant.

Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

Abstract: A refrigerant control system includes: a charge module configured to determine an amount of refrigerant that is present within a refrigeration system of a building; a leak module configured to diagnose that a leak is present in the refrigeration system based on the amount of refrigerant; and at least one module configured to take at least one remedial action in response to the diagnosis that the leak is present in the refrigeration system.

Abstract: The present invention includes a composition and method of producing aspirin in situ, the method comprising: identifying a subject in need of aspirin or aspirin-like compounds; and providing the subject with a composition comprising: a source of methyl salicylate, an acetyl donor, and L-Arginine, wherein the composition is effective to produce aspirin-triggered resolvins in the subject without the deleterious effect of the aspirin or aspirin-like compounds in the stomach.

Abstract: The present disclosure is directed to edible organogel compositions that comprise an organogelator and a flavor component, and processes for preparing the organogel compositions. The organogelator is ethyl cellulose or a combination of ethyl cellulose and an edible wax, preferably candelilla wax, rice bran wax, carnauba wax, paraffin, beeswax, polyethylene wax or combinations thereof. The ethyl cellulose preferably has an average ethoxyl content of from 45.0% to 47.0% by weight of the ethyl cellulose or from 48.0% to 49.5% by weight of the ethyl cellulose. The organogel compositions may be included as the flavor component in confectionery products, such as chewing gums.

Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.

Abstract: A refrigerated food container system includes a container defining an inner volume and a thermoelectric module arranged in thermal contact with at least one surface of the container. The thermoelectric module includes a first thermoelectric cooling device and a second thermoelectric cooling device in thermal contact with the first thermoelectric cooling device. A control module is configured to provide a first voltage to the first thermoelectric cooling device and provide a second voltage to the second thermoelectric cooling device.

Abstract: Systems and methods for purging lubricant from a first compressor to a second compressor are provided. A control module receives a lubricant purge command, shuts the second compressor to an OFF-mode while the first compressor remains in the ON-mode, restricts working fluid from an outlet of the second compressor from flowing into the first compressor and allows compressed working fluid discharged from an outlet of the first compressor to flow into the inlet of the second compressor such that lubricant in the second compressor flows into the first compressor.

Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.

Abstract: The present invention relates to antibodies that bind to IgE and their use in the treatment of autoimmune diseases, particularly Bullous Pemphigoid (BP) and Chronic Spontaneous Urticaria (CSU). The anti-IgE antibodies comprise a variant Fc domain that binds to the Fc receptor FcRn with increased affinity relative to a wild-type Fc domain. The anti-IgE antibodies may comprise a variant Fc domain comprising the amino acids Y, T, E, K, F and Y at EU positions 252, 254, 256, 433, 434 and 436, respectively, wherein the variant Fc domain binds to human FcRn with increased affinity relative to a wild-type human IgG Fc domain.

Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.

Abstract: A network model includes nodes, node property sets, authorization groups and authorization servers. The node property sets define how the nodes operate and authenticate. The nodes are member of the node property sets. The authorization groups are associated with the node property set. And, authorization servers are member of the authorization groups. In addition, a network model in a secure network environment has at least one community of interest. The network model includes at least one node being a member of a node property set that defines how the node operates and authenticates.